NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered peptides from LSPL? Mail in a sample (US only) and let us test it.

Test my supply
+2 more ↓
72%
Finnrick rating
#261 of 457 ranked vendors
40 of 57 classifiable tests passed
methodology · Purity focus
Finnrick analysis

LSPL's purity-focus record is strongest on GHK-Cu, where identity and purity look clean despite fill volatility. Tirzepatide is mixed with repeated purity misses but cleaner recent tests, while Retatrutide is the weakest and most volatile; absent batch identifiers make the evidence harder to tie across lots.

methodology →
vendor intelligence report
Vendor Intelligence Report: LSPL

LSPL’s Facebook-only front end traces through ZZQ’s admin email to a Chinese IT registrant, while clone-like peptide storefronts sit on a shared IP/CMS stack. The report also documents a forum ban for incentivized reviews and COA provenance disputes.

27 pages7 risk factors assessed12 Jun 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.06
86%
6
2
Tirzepatide
$0.50
77%
21
3
Ipamorelin
$0.80
68%
3
4
Retatrutide
$0.55
64%
24
5
Cagrilintide
$2.00
62%
3
6
BPC-157
$2.40
-
0
7
GLOW
$0.23
-
0
8
PT-141
-
-
0
10
TB-500
$1.50
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%6 Dec 2025: 71%6 Dec 2025: 71%10 Dec 2025: 70%10 Dec 2025: 70%11 Dec 2025: 71%11 Dec 2025: 71%11 Dec 2025: 70%13 Dec 2025: 69%13 Dec 2025: 70%16 Dec 2025: 69%16 Dec 2025: 69%22 Dec 2025: 69%22 Dec 2025: 70%29 Dec 2025: 70%29 Dec 2025: 70%1 Jan 2026: 70%1 Jan 2026: 71%7 Jan 2026: 70%15 Jan 2026: 69%19 Jan 2026: 69%29 Jan 2026: 70%29 Jan 2026: 69%18 Feb 2026: 69%18 Feb 2026: 68%20 Feb 2026: 69%20 Feb 2026: 69%20 Feb 2026: 69%22 Feb 2026: 69%4 Mar 2026: 70%6 Mar 2026: 69%6 Mar 2026: 69%19 Mar 2026: 70%5 May 2026: 70%8 May 2026: 70%2 Jun 2026: 71%13 Jul 2026: 71%13 Jul 2026: 71%14 Jul 2026: 72%21 Jul 2026: 72%8 Sep 2026: 72%2 Oct 2026: current 72%71%70%72%Dec 25Oct 26
Free peptide testing

Ordered peptides from LSPL? Mail in a sample (US only) and let us test it.

Test my supply
LSPL test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
8 Sep 2026
Pass
Retatrutide
lab nameView COA
21 Jul 2026
Pass
Tirzepatide
lab nameView COA
14 Jul 2026
Pass
Tirzepatide
lab nameView COA
13 Jul 2026
Pass
Tirzepatide
lab nameView COA
13 Jul 2026
Pass
Retatrutide
lab nameView COA
2 Jun 2026
Pass
Tirzepatide
lab nameView COA
8 May 2026
Pass
Retatrutide
lab nameView COA
5 May 2026
Pass
Tirzepatide
lab nameView COA
19 Mar 2026
Pass
Retatrutide
lab nameView COA
6 Mar 2026
Pass
Tirzepatide
lab nameView COA
1-10 of 57

About LSPL test results from Finnrick

LSPL is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 5 peptides and 57 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible LSPL peptides in this dataset are Cagrilintide (3 tests), GHK-Cu (6 tests) and Ipamorelin (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 57 recent tests.

Corrections
No corrections.
Free peptide testing

Ordered peptides from LSPL? Mail in a sample (US only) and let us test it.

Test my supply